

with more than fourteen years in service.

**EFFECTIVE DATE:** This correction is effective on February 11, 2004.

**FOR FURTHER INFORMATION CONTACT:** Frederick Sobeck, telephone (202) 267-7355.

#### Correction

■ In final rule FR Doc. 03-2679, published on February 4, 2003 (68 FR 5782), make the following corrections:

■ 1. On page 5782, in column 1 of the heading section, beginning on line five, correct "Amdt. Nos. 119-6, 121-284, 129-34, 135-81, and 183-11" to read "Amdt. Nos. 119-6, 121-296, 129-34, 135-87, and 183-11".

Issued in Washington, DC on January 30, 2004.

**Donald P. Byrne,**

*Assistant Chief Counsel for Regulations.*

[FR Doc. 04-2879 Filed 2-10-04; 8:45 am]

**BILLING CODE 4910-13-U**

## DEPARTMENT OF TRANSPORTATION

### Federal Aviation Administration

#### 14 CFR Parts 121, 125, and 129

[Docket No. FAA-2001-10910; Amendment Nos. 121-297, 125-41, and 129-37]

RIN 2120-AG90

#### Collision Avoidance Systems; Correction

**AGENCY:** Federal Aviation Administration (FAA), DOT.

**ACTION:** Final rule; correction.

**SUMMARY:** This document makes a correction to the amendment numbers in the final rule published in the **Federal Register** on April 1, 2003. That action revised the applicability of certain collision avoidance system requirements for airplanes.

**EFFECTIVE DATE:** This correction is effective on February 11, 2004.

**FOR FURTHER INFORMATION CONTACT:** Alberta Brown, telephone (202) 267-8321.

#### Correction

■ In the final rule FR Doc. 03-7653, published on April 1, 2003 (68 FR 15884), make the following correction:

■ 1. On page 15884, in column 1 in the heading section, beginning on line 4, correct "Amendment Nos. 121-286, 125-41, and 129-37" to read "Amendment Nos. 121-297, 125-41, and 129-37".

Issued in Washington, DC on January 30, 2004.

**Donald P. Byrne,**

*Assistant Chief Counsel for Regulations.*

[FR Doc. 04-2881 Filed 2-10-04; 8:45 am]

**BILLING CODE 4910-13-U**

## DEPARTMENT OF TRANSPORTATION

### Federal Aviation Administration

#### 14 CFR Parts 121, 125, and 135

[Docket No. FAA-2003-15682; Amendment Nos. 121-300 125-42, 135-89]

RIN 2120-AH89

#### Digital Flight Data Recorder Requirements—Changes to Recording Specifications and Additional Exceptions; Correction

**AGENCY:** Federal Aviation Administration (FAA), DOT.

**ACTION:** Final rule; correction.

**SUMMARY:** This document corrects amendment numbers assigned in the final rule published in the **Federal Register** on July 18, 2003. That action amended the flight data recorder regulations by expanding the recording specifications of certain data parameters for specified airplanes, and by adding aircraft models to the lists of aircraft excepted from the 1997 regulations.

**EFFECTIVE DATE:** This correction is effective on February 11, 2004.

**FOR FURTHER INFORMATION CONTACT:** Gary Davis, telephone (202) 267-8166.

#### Correction

■ In the correction to the final rule FR Doc. 03-18269, published on July 18, 2003 (68 FR 42932), make the following correction:

■ 1. On page 42932 in column one, in the heading section beginning on line 4, correct "Amendment Nos. 121-288, 125-42, 135-84" to read "Amendment Nos. 121-300, 125-42, 135-89".

Issued in Washington, DC on January 30, 2004.

**Donald P. Byrne,**

*Assistant Chief Counsel for Regulations.*

[FR Doc. 04-2876 Filed 2-10-04; 8:45 am]

**BILLING CODE 4910-13-U**

## DEPARTMENT OF TRANSPORTATION

### Federal Aviation Administration

#### 14 CFR Parts 121 and 129

[Docket No. FAA-2003-15653; Amendment Nos. 121-299 and 129-38]

RIN 2120-AH96

#### Flightdeck Security on Large Cargo Airplanes; Correction

**AGENCY:** Federal Aviation Administration (FAA), DOT.

**ACTION:** Final rule; correction.

**SUMMARY:** This document makes a correction to the amendment numbers in the final rule published in the **Federal Register** on July 18, 2003. That rule provided an alternative means of compliance to operators of all-cargo airplanes that are required to have a reinforced security flightdeck door.

**EFFECTIVE DATE:** This correction is effective on February 11, 2004.

**FOR FURTHER INFORMATION CONTACT:** Joe Keenan, (202) 267-9579.

#### Correction

In the final rule FR Doc. 03-18075 published on July 18, 2003, (68 FR 42874), make the following corrections:

■ 1. On page 42874, in column 1, in the heading section, beginning on line 4 correct "Amendment Nos. 121-287 and 129-37" to read "Amendment Nos. 121-299 and 129-38".

Issued in Washington, DC, on January 30, 2004.

**Donald P. Byrne,**

*Assistant Chief Counsel for Regulations.*

[FR Doc. 04-2877 Filed 2-10-04; 8:45 am]

**BILLING CODE 4910-13-U**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### 21 CFR Parts 529 and 556

#### Certain Other Dosage Form New Animal Drugs; Oxytetracycline

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by AlphaPharma, Inc. The supplemental NADA provides for use of oxytetracycline hydrochloride soluble

powder for skeletal marking of finfish fry and fingerlings by immersion.

**DATES:** This rule is effective February 11, 2004.

**FOR FURTHER INFORMATION CONTACT:** Joan C. Gotthardt, Center for Veterinary Medicine (HFV-130), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, (301) 827-7571, e-mail: [jgotthar@cvm.fda.gov](mailto:jgotthar@cvm.fda.gov).

**SUPPLEMENTARY INFORMATION:** Alpharma, Inc., One Executive Dr., P.O. Box 1399, Fort Lee, NJ 07024, filed a supplement to NADA 130-435 that provides for use of OXYMARINE (oxytetracycline hydrochloride) Soluble Powder for skeletal marking of finfish fry and fingerlings by immersion. The approval of this supplemental NADA relied on publicly available safety and effectiveness data contained in Public Master File (PMF) 5667 which were compiled under National Research Support Project 7 (NRSP-7), a national agricultural research program for obtaining clearances for use of new drugs in minor animal species and for special uses. The supplemental NADA is approved as of December 24, 2003, and the regulations are amended in 21 CFR part 529 by adding § 529.1660 to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

FDA has determined under 21 CFR 25.33(d)(4) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

#### List of Subjects

21 CFR Part 529

Animal drugs.

21 CFR Part 556

Animal drugs, Foods.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 529 and 556 are amended as follows:

#### PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 529 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

■ 2. Section 529.1660 is added to read as follows:

##### § 529.1660 Oxytetracycline.

(a) *Specifications.* Each gram of powder contains 366 milligrams (mg) of oxytetracycline hydrochloride.

(b) *Sponsor.* See No. 046573 in § 510.600 of this chapter.

(c) *Related tolerances.* See § 556.500 of this chapter.

(d) *Conditions of use in finfish—(1) Amount.* Immerse fish in a solution containing 200 to 700 mg oxytetracycline hydrochloride (buffered) per liter of water for 2 to 6 hours.

(2) *Indications for use.* For skeletal marking of finfish fry and fingerlings.

#### PART 556—TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD

■ 3. The authority citation for 21 CFR part 556 continues to read as follows:

**Authority:** 21 U.S.C. 342, 360b, 371.

##### § 556.500 [Amended]

■ 4. Section 556.500 *Oxytetracycline* is amended in paragraph (b) by removing "catfish, lobster, and salmonids" and by adding in its place "finfish, and lobster".

Dated: January 30, 2004.

**Steven D. Vaughn,**

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.  
[FR Doc. 04-2894 Filed 2-10-04; 8:45 am]

**BILLING CODE 4160-01-S**

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

##### Food and Drug Administration

##### 21 CFR Part 558

##### New Animal Drugs for Use in Animal Feeds; Monensin

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule; technical amendment.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Elanco Animal Health. The supplemental NADA provides for revised labeling for the use of single-ingredient monensin Type A medicated articles to make Type C medicated feeds used for the prevention and control of coccidiosis in feedlot cattle. The regulations are being amended to remove a redundant entry for use of monensin in Type C medicated cattle feeds.

**DATES:** This rule is effective February 11, 2004.

**FOR FURTHER INFORMATION CONTACT:** Janis R. Messenheimer, Center for Veterinary Medicine (HFV-135), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-7578, e-mail: [jmessenh@cvm.fda.gov](mailto:jmessenh@cvm.fda.gov).

**SUPPLEMENTARY INFORMATION:** Elanco Animal Health, A Division of Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285, filed a supplement to NADA 95-735 for use of RUMENSIN 80 (monensin sodium) Type A medicated article. The supplemental NADA provides revised labeling for Type C medicated feeds containing 10 to 30 grams per ton (g/ton) of monensin used for the prevention and control of coccidiosis caused by *Eimeria bovis* and *E. zuernii* in feedlot cattle. This revised labeling replaces labeling approved in 1998 for this indication (64 FR 5158, February 3, 1999). The supplemental application is approved as of December 12, 2003, and the regulations are amended in 21 CFR 558.355(f)(3)(vii) to remove indications for improved feed efficiency in cattle feeds containing 10 to 30 g/ton of monensin. This indication for use is already codified in 21 CFR 558.355(f)(3)(i) for cattle feeds containing 5 to 30 g of monensin per ton.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore,